logo
YouTube intros new top-podcast chart, letting you see exactly who's influencing America

YouTube intros new top-podcast chart, letting you see exactly who's influencing America

Edgar Cervantes / Android Authority
TL;DR YouTube is introducing a Weekly Podcast Shows chart, highlighting the top 100 in the US.
Listings will be updated each Wednesday.
For now this is US-only, but Google wants to expand to additional regions.
Considering that the iPod has long found itself replaced by more capable smartphones, it's legitimately impressive that podcasts have managed to stick around as a beloved media format. Sure, we've seen many evolve from audio to video-first formats, but the core idea of being able to listen to an on-demand conversation between talented hosts and their guests is one that's proven its worth. With podcasts as big as they are today, it's only understandable that listeners crave tools for helping them discover their next new podcast obsession, and this week Google's got a new one debuting on YouTube.
YouTube is introducing its new Weekly Podcast Shows chart. The inaugural list covers May 5 through May 11, and sorts out the top 100 podcasts available on the platform, based on their popularity among US audiences.
Stephen Schenck / Android Authority
As you'd only expect from a list of top podcasts in America in 2025, the list is a broad mix of true-crime shows, comedy, paranormal stuff, sports talk, right-wing influencers, and mainstream political commentary. You can expect to see Google update the list with the previous week's rankings every Wednesday.
Interestingly, Google's not keeping track of total views here (like we recently saw Spotify highlight with its own podcast listings), and instead using a metric based on overall minutes listened. That sounds like it has the potential to possibly giving longer-format podcasts a leg up — at least, if they can stay engaging long enough to keep YouTube audiences listening.
For now, this chart is only being produced for the US, but Google says that it's planning to expand that to more regions at some point — no word on a timetable just yet. The company also mentions a desire to bring more features to the chart. We can already think of a few we'd really like to see, including filters for genre, and maybe information on the latest available episode for all these entries. Are there any changes you'd like to implement? Share your ideas in the conversation below.
Got a tip? Talk to us! Email our staff at
Email our staff at news@androidauthority.com . You can stay anonymous or get credit for the info, it's your choice.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Today's NYT Mini Crossword Answers for June 22
Today's NYT Mini Crossword Answers for June 22

CNET

time28 minutes ago

  • CNET

Today's NYT Mini Crossword Answers for June 22

Looking for the most recent Mini Crossword answer? Click here for today's Mini Crossword hints, as well as our daily answers and hints for The New York Times Wordle, Strands, Connections and Connections: Sports Edition puzzles. Need some help with today's Mini Crossword? There are some tough clues today. Read on. And if you could use some hints and guidance for daily solving, check out our Mini Crossword tips. The Mini Crossword is just one of many games in the Times' games collection. If you're looking for today's Wordle, Connections, Connections: Sports Edition and Strands answers, you can visit CNET's NYT puzzle hints page. Read more: Tips and Tricks for Solving The New York Times Mini Crossword Let's get to those Mini Crossword clues and answers. The completed NYT Mini Crossword puzzle for June 22, 2025. NYT/Screenshot by CNET Mini across clues and answers 1A clue: Man's name with the same two vowels as BOAT, fittingly Answer: NOAH 5A clue: Watch in one sitting, as a TV series Answer: BINGE 6A clue: Mammal that cracks open sea urchins with rocks Answer: OTTER 7A clue: Publicist's concern Answer: BRAND 8A clue: Chooses, with "for" Answer: OPTS Mini down clues and answers 1D clue: Like some cold brew coffee Answer: NITRO 2D clue: How beer may be served Answer: ONTAP 3D clue: One helping to seal the deal Answer: AGENT 4D clue: Groups of buffalo Answer: HERDS 5D clue: ___ the Drag Queen, "RuPaul's Drag Race" winner who competed on "The Traitors" Answer: BOB

Workiva Inc. (WK) Appoints Astha Malik to Its Board of Directors
Workiva Inc. (WK) Appoints Astha Malik to Its Board of Directors

Yahoo

time37 minutes ago

  • Yahoo

Workiva Inc. (WK) Appoints Astha Malik to Its Board of Directors

Workiva Inc. (NYSE:WK) is one of the 11 Best Tech Stocks to Buy On the Dip. On May 29, Workiva Inc. (NYSE:WK) announced the appointment of Astha Malik, Chief Business Officer of Braze, to its board of directors. Malik brings 25 years of experience in driving growth and scaling high-growth SaaS companies. The company also released its Q1 2025 results on May 1. The revenue of $206 million grew 17% year-over-year driven by a 20% increase in subscription and support revenue. Both of these financial indicators surpass management's guidance despite a challenging environment characterized by a cautious buying environment and flat professional services revenue. A software engineer debugging a compliance code on a laptop in a modern office setting. After the earnings release, analyst Alexander Sklar from Raymond James maintained an Overweight rating on Workiva Inc. (NYSE:WK) lowering the price target from $125 to $105. The analyst noted the company showed strong bookings in Q1 however, the tough macroeconomic environment led to a conservative outlook by Raymond James. Regardless, Workiva Inc. (NYSE:WK) maintained its full-year revenue guidance at $864 million to $868 million. Workiva Inc. (NYSE:WK) is a technology company that operates a cloud-based platform that enables organizations to streamline and automate financial, sustainability, and compliance reporting processes. Its SaaS platform combines ERP, HCM, and CRM applications, supporting real-time collaboration and integrated reporting across teams. While we acknowledge the potential of WK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Melden Sie sich an, um Ihr Portfolio aufzurufen.

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity

Yahoo

time37 minutes ago

  • Yahoo

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated coverage of the stock with a 'Buy' rating and a $72 price target. The research firm remains bullish about the company's prospects owing to the strong potential of its drug candidates. A scientist in a lab coat examining a Petri dish containing a biopharmaceutical culture. The company's partnership with Takeda on Rusfertide to treat polycythemia Vera (PV) and oral IL-23 (icotrokinra) is one of the developments that underscore the research firm's favorable rating. Rusfertide demonstrated strong potential in PV patients in phase 3 trials, affirming its potential to address unmet needs. Citi is especially bullish about adding Rusfertide to existing therapies to expand its use case. In addition, the firm echoed the company's strategic partnership with Johnson & Johnson for multiple inflammation indications. According to Citi, Protagonist Therapeutics shares have outperformed over the past three months, going up by a 40% gain compared to a 2% gain of the S&P 500. It expects the company's combined revenues to climb to $700 million by 2032, above consensus estimates of $680 million. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopharmaceutical company that develops peptide-based drugs to treat various diseases, including rare and prevalent ones. Its pipeline includes treatments for blood disorders like polycythemia Vera and inflammatory conditions like ulcerative colitis and psoriasis. While we acknowledge the potential of PTGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store